The Therapeutic Products Directorate (TPD), the Biologic and Radiopharmaceutical Drugs Directorate (BRDD), and the Natural and Non-Prescription Health Products Directorate (NNHPD) have released their Drug Submission Performance Annual Reports for the Fiscal Year 2020-2021 (April 1, 2020 to March 31, 2021). The reports contain information regarding pharmaceutical, biologic and radiopharmaceutical drug submission review activity including average approval times.
The TPD, BRDD and NNHPD 2020-2021 reports also highlight significant events that occurred during the spring of 2020 such as the COVID-19 pandemic, and includes a section on applications under: (1) the Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19 (see our article here), and (2) the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 (see article here).
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.